RATIONALE: We previously reported that mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is necessary for oxidized phospholipids to induce monocyte chemoattractant protein-1 (MCP-1) secretion by human aortic endothelial cells. We also reported that inhibition of tyrosine phosphatases including MKP-1 ameliorated atherosclerotic lesions in mouse models of atherosclerosis. OBJECTIVE: This study was conducted to further investigate the specific role of MKP-1 in atherogenesis. METHODS AND RESULTS: We generated MKP-1(-/-)/apoE(-/-) double-knockout mice. At 24weeks of age, the size, macrophage and dendritic cell content of atherosclerotic lesions of the aortic root were significantly lower ( approximately -41% for lesions and macrophages, and approximately -78% for dendritic cells) in MKP-1(-/-)/apoE(-/-) mice when compared with apoE(-/-) mice. Total cholesterol (-18.4%, p=0.045) and very low-density lipoprotein (VLDL)/low-density lipoprotein (LDL) cholesterol (-20.0%, p=0.052) levels were decreased in MKP-1(-/-)/apoE(-/-) mice. Serum from MKP-1(-/-)/apoE(-/-) mice contained significantly lower levels of MCP-1 and possessed significantly reduced capability to induce monocyte migration in vitro. Moreover, peritoneal macrophages isolated from MKP-1(-/-)/apoE(-/-) mice produced significantly lower levels of MCP-1 when compared to peritoneal macrophages from apoE(-/-) mice. Furthermore, MKP-1(-/-)/apoE(-/-) mice had significantly reduced serum hydroxyeicosatetraenoic acids (HETEs) levels, which have been reported to induce MCP-1 levels. CONCLUSIONS: Our results demonstrate that MKP-1 deficiency significantly decreases atherosclerotic lesion development in mice, in part, by affecting MCP-1 levels in the circulation and MCP-1 production by macrophages. MKP-1 may serve as a potential therapeutic target for the treatment of atherosclerotic disease.
RATIONALE: We previously reported that mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is necessary for oxidized phospholipids to induce monocyte chemoattractant protein-1 (MCP-1) secretion by human aortic endothelial cells. We also reported that inhibition of tyrosine phosphatases including MKP-1 ameliorated atherosclerotic lesions in mouse models of atherosclerosis. OBJECTIVE: This study was conducted to further investigate the specific role of MKP-1 in atherogenesis. METHODS AND RESULTS: We generated MKP-1(-/-)/apoE(-/-) double-knockout mice. At 24weeks of age, the size, macrophage and dendritic cell content of atherosclerotic lesions of the aortic root were significantly lower ( approximately -41% for lesions and macrophages, and approximately -78% for dendritic cells) in MKP-1(-/-)/apoE(-/-) mice when compared with apoE(-/-) mice. Total cholesterol (-18.4%, p=0.045) and very low-density lipoprotein (VLDL)/low-density lipoprotein (LDL) cholesterol (-20.0%, p=0.052) levels were decreased in MKP-1(-/-)/apoE(-/-) mice. Serum from MKP-1(-/-)/apoE(-/-) mice contained significantly lower levels of MCP-1 and possessed significantly reduced capability to induce monocyte migration in vitro. Moreover, peritoneal macrophages isolated from MKP-1(-/-)/apoE(-/-) mice produced significantly lower levels of MCP-1 when compared to peritoneal macrophages from apoE(-/-) mice. Furthermore, MKP-1(-/-)/apoE(-/-) mice had significantly reduced serum hydroxyeicosatetraenoic acids (HETEs) levels, which have been reported to induce MCP-1 levels. CONCLUSIONS: Our results demonstrate that MKP-1 deficiency significantly decreases atherosclerotic lesion development in mice, in part, by affecting MCP-1 levels in the circulation and MCP-1 production by macrophages. MKP-1 may serve as a potential therapeutic target for the treatment of atherosclerotic disease.
Authors: Filip K Swirski; Peter Libby; Elena Aikawa; Pilar Alcaide; F William Luscinskas; Ralph Weissleder; Mikael J Pittet Journal: J Clin Invest Date: 2007-01 Impact factor: 14.808
Authors: J A Berliner; M Navab; A M Fogelman; J S Frank; L L Demer; P A Edwards; A D Watson; A J Lusis Journal: Circulation Date: 1995-05-01 Impact factor: 29.690
Authors: René R S Packard; Elena Maganto-García; Israel Gotsman; Ira Tabas; Peter Libby; Andrew H Lichtman Journal: Circ Res Date: 2008-10-02 Impact factor: 17.367
Authors: Swarup K Chakrabarti; Banumathi K Cole; Yeshao Wen; Susanna R Keller; Jerry L Nadler Journal: Obesity (Silver Spring) Date: 2009-06-11 Impact factor: 5.002
Authors: Sangderk Lee; Konstantin G Birukov; Casey E Romanoski; James R Springstead; Aldons J Lusis; Judith A Berliner Journal: Circ Res Date: 2012-08-31 Impact factor: 17.367
Authors: Michal S Hoffmann; Prachi Singh; Robert Wolk; Krzysztof Narkiewicz; Virend K Somers Journal: Atherosclerosis Date: 2013-10-11 Impact factor: 5.162
Authors: Narges Amini; Joseph J Boyle; Britta Moers; Christina M Warboys; Talat H Malik; Mustafa Zakkar; Sheila E Francis; Justin C Mason; Dorian O Haskard; Paul C Evans Journal: Atherosclerosis Date: 2014-06-12 Impact factor: 5.162